Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

Next Previous
X
Search
Trial Profile

Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadolinium chelated polysiloxane based nanoparticle (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms Nano-SMART

    • Most Recent Events

    • 02 May 2023 Planned End Date changed from 10 Sep 2024 to 10 Sep 2027.
    • 02 May 2023 Planned primary completion date changed from 10 Apr 2023 to 10 Apr 2026.
    • 16 Nov 2021 According to an NH TherAguix media release, the U.S. FDA has accepted the company's Investigational New Drug Application for its drug candidate AGuIX to be combined with radiotherapy to increase radiotherapy efficacy for solid cancers. The Dana Farber and Brigham & Women's Hospital (DFBWH, Harvard Medical School, Boston) will be the sponsor of the first trial to be launched by the company in the US and which is planned to begin in the first quarter of the year 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top